Mazdutide vs Pemvidutide
Head-to-head comparison of Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mazdutide | Pemvidutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | ~5,000 Da | N/A |
| Half-Life | 5-7 days | Approximately 1 week |
| Amino Acids | 37 | N/A |
| Typical Dose | 1-6 mg weekly in obesity trials | Trial-dependent; once-weekly SC titration |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 18 |
| Research Status | Clinical | Clinical |
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.